Jiangsu Hengrui Pharmaceuticals Co.,Ltd (600276.SS) News
Track canonical SquawkNews coverage tagged to 600276.SS, Jiangsu Hengrui Pharmaceuticals Co.,Ltd. This hub brings together deduplicated headlines about shanghai stock exchange, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 2 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Novo Nordisk to pay $300 million upfront to license experimental GLP-1 pill from Hengrui
Novo Nordisk will pay $300 million upfront to Jiangsu Hengrui Pharmaceuticals for rights to experimental GLP-1 pill HRS-1596, with Hengrui eligible for milestone payments up to $2.3 billion. Novo gets development, manufa
MNA | Sep 29, 2026, 05:55 AM UTC
M
Hengrui Pharma licenses GLP-1/GIP drug HRS-1596 to Novo Nordisk in deal worth up to $2.6 billion
Novo Nordisk gets exclusive rights outside mainland China, Hong Kong, Macau and Taiwan. Hengrui will receive $300 million upfront plus milestones and royalties; closing is expected in Q4 2026, subject to U.S. antitrust c
MNA | Sep 29, 2026, 04:30 AM UTC